A bifunctional MAPK/PI3K antagonist for inhibition of tumor growth and metastasis

Responses to targeted therapies frequently are brief with patients relapsing with drug resistant tumors. For oncogenic MEK and BRAF inhibition, drug resistance commonly occurs through activation of PI3K/AKT/mTOR signaling and immune checkpoint modulation, providing a robust molecular target for conc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Galbán, Stefanie, Apfelbaum, April A., Espinoza, Carlos, Heist, Kevin, Haley, Henry, Bedi, Karan, Ljungman, Mats, Galbán, Craig J., Luker, Gary D., Van Dort, Marcian, Ross, Brian D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669819/
https://ncbi.nlm.nih.gov/pubmed/28775144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0207
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados